INDOLEAMINE 2,3 DIOXYGENASE AS AN IMMUNOTHERAPEUTIC TARGET BRINGS A NEW HOPE FOR CANCER PATIENTS by Asghar, Kashif & Loya, Asif
JOURNAL OF CANCER & ALLIED SPECIALTIES 1
REVIEW ARTICLE J Cancer Allied Spec 2018;4(3):2
INDOLEAMINE 2,3 DIOXYGENASE AS AN IMMUNOTHERAPEUTIC TARGET BRINGS 
A NEW HOPE FOR CANCER PATIENTS
Kashif Asghar1, Asif Loya2
1Department of Basic Sciences Research, Shaukat Khanum Memorial Cancer Hospital and Research Centre, 
Lahore, Pakistan, 2Department of Pathology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, 
Lahore, Pakistan
Received: 22 May 2018 / Accepted: 17 September 2018
Abstract
Therapeutic manipulation of immune system in cancer has been an extensive area of research in the field of 
oncoimmunology. Immunotherapy helps the immune system to combat against cancer. Tumour cells take an edge of 
immunosuppressive mechanisms and inhibit antitumour immune responses. Indoleamine 2,3-dioxygenase (IDO) is 
an immunosuppressive enzyme which is involved in tumour immune escape mechanism in various cancers. IDO can 
degrade the tryptophan into kynurenines and has an ability to enhance the immune tolerance through mammalian target 
of rapamycin pathway general control nonderepressible 2 (GCN2) pathway and induction of regulatory T (T-regs) cells. 
IDO-induced T-regs suppress the local immune responses in the tumour microenvironment and promote metastasis. 
IDO overexpression in various cancers is associated with poor prognosis. Several preclinical and clinical trials have 
been proceeding and recommend that IDO inhibitor may be an influential tool against a wide range of cancers. IDO 
inhibitors as adjuvant therapeutic agents may also have clinical implications. Thus, IDO has the potential to be used 
as an immunotherapeutic target. This review discusses the promising role of IDO in cancer and its implication in 
immunotherapy.
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Introduction
Immunotherapy uses specific parts of an individual’s 
immune system to fight against cancer. Cancer 
immunotherapy is promptly progressing and now is 
considered as the “fifth pillar” of cancer therapy.[1] 
Immunotherapeutic approaches include adoptive cellular 
immunotherapy, cancer vaccines, oncolytic viruses and 
immune checkpoint blockade.[2] It has been established 
that the defective immune system plays a critical role in 
cancer development.[3] Some malignant cells have the 
capacity to manipulate their own characteristics as well 
as cells in their microenvironment to form “successful” 
tumours thus evading the tumour immunosurveillance 
system.[1] Cancer cells can escape the immune attack 
through various complex mechanisms, including 
tumour induced immunosuppression through the 
upregulation of immunosuppressive enzymes, such 
as indoleamine 2,3-dioxygenase (IDO/IDO1).[4,5] IDO 
is a heme-containing enzyme involved in tryptophan 
catabolism.[6] IDO induces immunosuppression through 
tryptophan degradation and generation of tryptophan 
metabolites.[6] Tryptophan degradation by IDO directly 
affects T-cell proliferation through the activation of 
the GCN2 kinase pathway.[7] Tryptophan metabolites 
(Kynurenines) also have the potential to induce apoptosis 
in lymphocytes.[8] T-cell immunity may be inhibited by 
IDO through induction of differentiation and maturation 
of T-regs.[9] Overexpression of IDO is involved in 
immunosuppression and tolerance.[10] IDO producing cells 
are found at various immune tolerance sites, including 
thymus, placenta, anterior chamber of eye, mucosa of gut 
and epididymis.[11-13]
IDO is expressed by human monocyte-derived 
macrophages and dendritic cells (DC).[14,15] Role of IDO 
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and its mode of action on cancer growth and immune 
evasion are still nascent in human cancer research. 
Numerous studies have documented a probable association 
between various clinical or immunologic parameters and 
IDO expression. Enhanced IDO expression in human 
cancer patients is linked with metastasis and predicts poor 
patient survival.[16] IDO is involved in tumour immune 
escape.[17] This review describes the involvement of IDO 
in various malignancies and proposes future prospects of 
IDO as immunotherapeutic target.
IDO in Breast Cancer
IDO protein is expressed in solid tumours such as 
breast cancer.[18] The involvement of IDO in breast 
cancer pathogenesis has been outlined in Table 1. IDO 
overexpression has an autonomous prognostic significance 
in basal-like breast carcinoma (BLBC) and is linked with 
morphological medullary features. Medullary breast 
carcinoma (MBC) has a better prognosis than non-MBC, 
but IDO is overexpressed at mRNA level in BLBC and 
MBC as compared to non-MBC. Tumour-infiltrating 
lymphocytes (TILs) reported in both MBC and BLBC. 
IDO expression is correlated with TILs.[19] IDO is involved 
in metastasis formation and tumour immune escape in 
murine breast cancer cell lines as well. IDO+ tumour 
grows faster than IDO− tumours in immunodeficient severe 
combined immunodeficiency mice. IDO1 is involved 
in breast tumour growth and spontaneous pulmonary 
metastasis formation.[20] Soliman et al. analysed an 
expression of IDO protein in 203 breast cancer cases. IDO 
overexpression was observed in ER+ (oestrogen receptor) 
tumour as compared to the ER− tumours (P = 0.0064). This 
study gave a new dimension to the ongoing clinical trials 
of IDO inhibitors in the metastatic breast cancer. They 
proposed further studies to understand the complicated 
role of IDO in breast cancer progression at different stages 
of the disease.[21]
Another murine breast cancer model research provided 
evidence that gene silencing of IDO is a potent approach to 
enhance the efficacy of DC-based cancer immunotherapy. 
IDO-silenced DCs improve cytotoxic T lymphocyte activity 
and tumour antigen-specific T-cell proliferation. IDO 
targeted inhibition in DCs may be a convenient resolution 
to boost the efficiency of DC vaccine in clinics.[22]
IDO overexpression was found in myeloid-derived 
suppressive cells (MDSCs), extracted from fresh breast 
Table 1: Comprehensive review of indoleamine 2,3‑dioxygenase involvement in breast cancer
Year Investigator Description
2012 Jacquemier et al.[19] IDO overexpression is associated with morphological medullary features and has indepen‑
dent prognostic value in BLBC
2012 Levina et al.[20] IDO1 expression has immunological and non‑immunological effects on breast tumour 
growth and spontaneous pulmonary metastasis formation
2013 Soliman et al.[21] Higher IDO expression is observed in tumours with ER+phenotype than ER ‑ tumours
2013 Zheng et al.[22] IDO gene silencing may enhance the efficacy of (DC)‑based cancer immunotherapeutic
2013 Yu et al.[23] MDSCs suppress the anti‑tumour immune responses by IDO expression in breast cancer
2014 Isla Larrain et al.[24] In vitro and in silico gene expression revealed that IDO is expressed in a (TNBC) subgroup. 
IDO is involved in the tumour immune escape
2015 Salvadori et al.[25] A decreased IDO expression is noted in cultured cancer cells of breast cancer patients when 
paclitaxel is given in combination with IDO inhibitor. It may be a new therapeutic strategy 
for breast cancer
2016 Chen et al.[26] IDO inhibitors in combination with chemotherapeutic agents improve antitumor responses 
in breast cancer mouse model
2017 Kim et al.[27] IDO expression is associated with BLBC. IDO inhibition may play a key role in the treatment 
of (BL) TNBC
2017 Noonepalle et al.[28] IDO1 methylation regulates anti‑immune responses in breast cancer subtypes. IDO methyla‑
tion can be used as a prognostic biomarker for IDO inhibitor based immunotherapy
IDO: Indoleamine 2,3‑dioxygenase, BL: BASAL‑like, BLBC: BL breast carcinoma, DC: Dendritic cell, MDSCs: Myeloid‑derived suppressive cells, 
TNBC: Triple negative breast cancer
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cancer tissues. It was associated with a high frequency of 
forkhead box P3 (Foxp3+) T-regs in lymph node metastasis 
and tumours. The role of signal transducer and activator 
of transcription 3 (STAT3) in IDO expression and IDO-
dependent MDSC-mediated immunosuppression on T 
cells was reported in this study.[23] IDO expression was 
detected in the sub-group of triple negative breast cancer 
(TNBC).
Furthermore, in silico studies verified the expression of 
IDO as well.[24] 1-Methyl-DL-tryptophan (D-1MT) is an 
IDO inhibitor which has therapeutic significance when 
given in combination with chemotherapeutic agents for 
breast cancer treatment.[25] Paclitaxel in combination with 
D-1MT decreased IDO expression in cultured cells from 
the breast tumour microenvironment.[25] Similar results 
were obtained in a breast cancer mouse model using 
NLG-919 (IDO inhibitor).[26]
A recently published data revealed that IDO1 expression 
is linked with TNBC with the BL phenotype and increased 
stromal lymphocytic infiltration. IDO1 immune checkpoint 
blockade may play a crucial role in the treatment of 
patients with TNBC.[27] Anti-immune responses exhibited 
by breast cancer subtypes are regulated by methylation 
of IDO1. IDO methylation can be used as a prognostic 
biomarker for IDO inhibitor based immunotherapy.[28]
IDO in Colorectal Cancer (CRC)
CRC is one of the major public health problems in the 
world.[29] The role of IDO in CRC has been outlined in 
Table 2. IDO1 expression is an independent prognostic 
factor in the pT1-4N1Mx-staged CRC.[30] Expression was 
associated with metachronous metastases and overall 
survival. IDO1 is a promising prognostic indicator in 
CRC identified by Ferdinande et al.[30] A murine model 
study indicates that IDO1 induces tumour proliferation 
and growth of neoplastic epithelium in a cell-autonomous 
fashion through activation of β-catenin signalling 
and kynurenine metabolites production. These results 
have considerable implications for IDO1 inhibitors as 
immunotherapeutic agents for IDO1- expressing colitis-
associated and sporadic colonic neoplasms.[31]
Daniel et al. (2015) measured the activity of IDO in 
patients with CRC. Quantification of IDO enzymatic 
activity was performed through high-performance liquid 
chromatography (HPLC) in the serum of 68 patients. IDO 
activity was observed high in patients with CRC. They 
suggested an association between IDO activity and CRC; 
further studies on IDO activity are required to establish it 
as a reliable serum biomarker of CRC.[32]
A recently published data about IDO1 expression also 
revealed that it is involved in the progression of CRC and 
is linked with impaired clinical prognosis. In this study, 
they analysed the expression of IDO1 and beta-catenin 
proteins by immunohistochemistry on the tissue samples 
of 192 CRC patients. IDO1-regulated molecular pathway 
was demonstrated to upregulate abnormal beta-catenin 
expression in the nucleus and cytoplasm of CRC patients 
having a low mutation rate of adenomatous polyposis coli, 
Table 2: Indoleamine 2,3‑dioxygenase involvement in colorectal cancer
Year Investigator Description
2012 Ferdinande et al.[30] High IDO1 expression at the tumour invasion is associated with (CRC) progression and 
correlates with impaired clinical outcome, implying that IDO1 is an independent prognostic 
marker for CRC
2013 Thaker et al.[31] IDO1 is involved in colitis‑associated tumorigenesis in mice. The epithelial cell‑autonomous 
survival advantage supported by IDO1 to colon epithelial cells demonstrate its potential as a 
therapeutic target
2015 Eyraud et al.[32] IDO activity is higher in patients with CRC compared with those without CRC. This study 
is the first step to establish that IDO enzymatic activity quantification is a reliable serum 
marker for CRC
2016 Chen et al.[33] IDO1 regulated molecular pathway led to the abnormal expression of beta‑catenin in the 
nucleus and cytoplasm of CRC patients with a low mutation rate of (APC), endorsing IDO1 is 
an appealing target for immunotherapy in CRC
CRC: Colorectal cancer, APC: Adenomatous polyposis coli, IDO: Indoleamine 2,3‑dioxygenase
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thus suggesting IDO1 an attractive immunotherapeutic 
target in CRC.[33]
Engin et al. indicated that high IDO immunostaining 
score is a strong predictor for lymph node metastasis.[29] 
IDO expression allows cancer subsets to evade immune 
attack in colorectal tumour cells. However, a suitable tool 
for the perseverance of undetected tumour cells does not 
exist that may be responsible for recurrent CRC. They 
recommended IDO immunostaining for histopathological 
evaluation of CRC cases.[29]
IDO in Haematological Malignancies
Haematological malignancies are cancers that affect the 
blood and lymph system. IDO expression and activity are 
upregulated in numerous haematological malignancies 
[Table 3]. Hoshi et al. investigated the expression of IDO 
in Adult T-cell leukaemia/lymphoma (ATLL) cell and the 
chemotherapeutic effect on IDO-initiating L-Tryptophan 
catabolism in ATLL patients. Level of IDO mRNA 
expression and enzymatic activity of IDO in ATLL cells 
were noticeably enhanced in ATLL patients compared to 
healthy individuals. IDO was strongly expressed at tissue 
level as well.[34] Lindström et al. determined activity and 
expression of IDO for chronic lymphocytic leukaemia 
(CLL) in 49 patients. Enhanced activity of IDO was 
observed in the CLL patients as compared to control, but 
in peripheral blood mononuclear cells mostly representing 
the malignant B cells, the gene expression of IDO1 and 
IDO2 was reduced. They found that IDO activity in CLL 
patients is associated with disease progression, even though 
it originates from cells other than malignant B cells.[35]
A comprehensive study conducted to investigate the IDO1 
expression and function in 21 children with acute myeloid 
leukaemia (AML), [10 AML, 9 B-cell precursor (BCP)-
ALL, one infant acute leukaemia with MLL rearrangement 
and 1 T-cell ALL] and in one patient with Ph+ chronic 
myeloid leukaemia. IDO activity was measured by reverse 
phase-HPLC. They found functional IDO1 expression in 
blast cells from of childhood AML subset, but not those 
from BCP-ALL or T-cell ALL. STAT3 inhibitors may 
effectively disrupt IDO1 expression by AML cells, thus 
in favour of anti-leukaemia immune responses tipping 
T helper type 1/2 (Th1/Th2) equilibrium.[36] Nakamura 
et al. explored the therapeutic potential of IDO inhibitor, 
D-1MT with cyclophosphamide (CY) using an IDO-
positive B-cell lymphoma mouse model. D-1MT in 
Table 3: Indoleamine 2,3‑dioxygenase involvement in haematological malignancies
Year Investigator Description
2009 Hoshi et al.[34] IDO is highly expressed in adult T‑cell leukaemia/lymphoma. IDO‑initiating L‑tryptophan 
catabolism changes with chemotherapy
2012 Lindström et al.[35] High IDO activity was observed in chronic lymphocytic leukaemia patients as compared to 
control. Increased IDO activity may affect disease progression
2012 Folgiero et al.[36] IDO1 is expressed by a subset of childhood acute myeloid leukaemia and restrains IFN‑γ pro‑
duction by T‑cells
2013 Nakamura et al.[37] IDO inhibitor in combination with cyclophosphamide is an effective treatment for IDO‑positive 
lymphoma in a mouse model. IDO inhibition might offer a favourable treatment strategy for 
lymphoma
2014 Liu et al.[38] IDO1 upregulation in non‑Hodgkin lymphoma tissues could induce local immune tolerance by 
infiltration of FoxP3+T‑regs in the tumour microenvironment. This could be a novel mecha‑
nism of immune escape
2014 Choe et al.[39] IDO is associated with the adverse clinical outcomes in (HL). IDO is an independent prognostic 
factor in nodular sclerosis HL
2014 Folgiero et al.[40] IDO1 expression by leukaemia blasts negatively affects the prognosis of childhood (AML). 
IDO can be targeted, in adjunct to current chemotherapy strategies, to improve the clinical 
outcome of children with AML
2016 Mansour et al.[41] High IDO expression in mesenchymal stem cells and increased levels of T‑regs play pivotal role 
in the pathogenesis of AML
IDO: Indoleamine 2,3‑dioxygenase, HL: Hodgkin lymphoma, AML: Acute myeloid leukaemia, IFN‑γ: Interferon gamma
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combination with CY was recommended by them as 
an effective IDO-positive lymphoma treatment. These 
findings suggest that inhibition of IDO might offer a 
therapeutic approach for lymphoma.[37]
A recently published study demonstrated the role of IDO 
in non-Hodgkin lymphoma (NHL). They identified IDO1 
upregulation in NHL tissues. They suggested that IDO has 
a critical role in immune escape mechanism in NHL.[38] 
IDO is not only involved in the non-HL pathogenesis but 
also the HL. A study conducted by Choe et al. described 
IDO role in the HL microenvironment. They identified HL 
tissues with IDO positive cells. This study was the first of 
its kind in defining IDO as a principle immune-modulator 
and its involvement to adverse clinical outcomes of HL.[39] 
A research published by Folgiero et al., in 2014, which 
was the continuation of his previous work published in 
2012, suggested expression of IDO1 by leukaemia blasts 
adversely affects childhood AML prognosis. The 8-year 
event-free survival from a clinical standpoint was markedly 
worse in IDO-expressing children as compared to non-
expressing ones. Chemotherapeutic agents in combination 
with IDO inhibitors were proposed by them to improve the 
clinical outcomes in the children with AML.[40] Another 
study on AML revealed that elevated level of T-regs 
has relationship with enhanced expression of IDO in 
mesenchymal stem cells which, in turn, responsible for 
immunosuppression in the tumour microenvironment. IDO 
has the main role in the pathogenesis of AML.[41]
IDO in Prostate Cancer
Prostate cancer is the most commonly diagnosed 
malignancy and a leading cause of mortality worldwide.[42] 
Overexpression of IDO gene was observed in the prostate 
cancer patients [Table 4]. Feder-Mengus et al. evaluated 
the expression of IDO and few other genes in benign 
prostatic hyperplasia (BPH) and prostate-specific antigen 
(PCA) tissues in 76 patients. IDO gene expression was 
quantitatively higher (P = 0.00001) and more repeatedly 
detectable (P = 0.00007) in PCA tissues in comparison 
with BPH. In serum analysis of these patients indicated 
an association between kynurenine/tryptophan ratio 
and IDO gene expression.[43] The same kind of results 
identified by Provenzano et al. that IDO has potential to 
use as biomarker of malignant transformation in prostate 
cancers and warranted further research in PCA patients.[44]
Gray et al., in 2009, identified the upregulation of 
tumour IDO and transforming growth factor-beta in 
more advanced prostate cancer. They proposed that 
immunotherapy clinical trials in prostate cancer patients 
will be more fruitful if conducted in less advanced 
disease.[45] Matos et al. pointed out the role of IDO in 
prostate cancer and suggested that IDO inhibition has 
clinical implication in prostate cancer.[46]
IDO in Pancreatic Cancer
IDO upregulation is associated with an increased number 
of T-regs in metastatic pancreatic ductal adenocarcinoma 
cells.[47] T-regs are key mediators of peripheral tolerance 
and have immunosuppressive activity.[48] Low numbers 
of T-regs in pancreatic tumours were found to have a 
markedly better survival in comparison with high T-regs 
number in tumours.[49] Kobayashi et al. investigated the 
localization and prevalence of CD8+ lymphocytes, IDO 
expression and FOXP3+ T-regs in intraductal papillary 
mucinous neoplasms (IPMNs) by immunohistochemistry 
in 39 cases. They observed IDO expression in the tumour 
Table 4: Indoleamine 2,3‑dioxygenase involvement in prostate cancer
Year Investigator Description
2008 Feder‑Mengus et al.[43] High expression of IDO gene was explicitly detectable in (PCA)
2008 Provenzano et al.[44] IDO gene expression, recurrently detectable in PCA and associated with (AMACR) expres‑
sion, seems to qualify as a marker of malignant transformation in prostate cancers
2009 Gray et al.[45] IDO, TGF‑β upregulation and induction of T‑regs in an immunosuppressive intratumoral 
cytokine milieu identified in more advanced prostate cancer
2016 Matos et al.[46] IDO is produced constitutively by PC3 (human prostate cancer cell line) cells and its ex‑
pression increase when the cells are exposed to IFN‑γ
IDO: Indoleamine 2,3‑dioxygenase, PCA: Prostate‑specific antigen, AMACR: Alpha‑methylacyl‑CoA racemace, TGF‑β: Transforming growth 
factor beta
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was positively correlated with the prevalence of T-regs in 
IPMNs.[50] Another study conducted by Ikemoto et al. to 
evaluate weather IDO and FOXP3+ T-regs interaction play a 
role in IPMN in pathological aggressiveness. They observed 
that the IDO-positive patient cells had a considerably higher 
recurrence than those with less IDO-positive cells. The 
aggressiveness of IPMNs is correlated with the involvement 
of FOXP3+ cells. IDO-positive cells in IPMNs can induce 
an increase in the FOXP3+ cells.[51] Natural Killer (NK) 
cells are key components in the innate immune system 
and are capable of destroying the cancer cells directly. 
Dysfunction of NK cells has been investigated in pancreatic 
cancer.[52] Induction of IDO by pancreatic cancer cells 
promotes NK cell dysfunction.[53] IDO helps pancreatic 
cancer cells to evade immunosurveillance[53] [Table 5].
IDO as an Immunotherapeutic Target
IDO is involved in immune system regulation. IDO 
upregulation is associated with poor prognosis in various 
cancers[20,30,34,35,39,41,43,51] but few studies suggested that 
increased expression of IDO was linked with favourable 
prognosis.[19,46] Further studies are required in view of 
the contradictory findings, to comprehend this complex 
role of IDO in various cancers. At present, in clinical 
stage, three IDO inhibitors are in commercial production 
as immunotherapeutic agents in breast cancer treatment. 
These include indoximod (NLG2101) developed by 
NewLink Genetics™,[54] INCB024360 developed by 
Incyte™[55,56] and NLG919 licensed to Genentech™.[57] 
Two therapies (NCT01042535 and NCT01792050) have 
been exclusively designed to treat HER2-positive breast 
cancer in combination with AD.p53 DC vaccine and 
docetaxel, respectively.[58] Another immunotherapy is 
available for patients with metastatic pancreatic cancer 
(NCT02077881).[59,60] NCT01560923 is currently 
approved for the individuals with refractory metastatic 
prostate carcinoma.[61,62] IDO-2 is a recently discovered 
IDO isoform.[63] Future studies on the role of IDO-2 should 
be focused as well in cancer. Therapeutic implications of 
IDO have significant outcomes.
Evidence Acquisition
The search strategy used the following keywords: 
‘Immunotherapy’ or ‘IDO’ or ‘Breast cancer’ or ‘Colon 
cancer’ or ‘Haematological malignancies’ or ‘Prostate 
cancer’ or ‘Pancreatic cancer.’ Three electronic databases 
(PubMed/MEDLINE, SCOPUS and GOOGLE SCHOLAR) 
were searched for articles published between 2008 and 2017. 
The most relevant articles were extracted from the literature.
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